N/A
N=139
Standing Cognition and Co-morbidities of POTS Evaluation
Postural Tachycardia Syndrome · Ehlers-Danlos Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT03602482 ↗Enrolled (actual)
139
Serious AEs
0.0%
Results posted
Apr 2021
Primary outcome: Primary: Executive Function (Stroop Word-color Test) — 48; 49; 50; 58 Testing Scores
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Standing (Behavioral); Supine (Behavioral)
- Age
- Pediatric, Adult · 13+ yrs
- Sex
- All
- Sponsor
- Milton S. Hershey Medical Center
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Executive Function (Stroop Word-color Test) |
48; 49; 50; 58; 45; 54 | — |
| SECONDARY Attention Score Using Cogstate Identification Task |
2.78; 2.78; 2.70; 2.68; 2.74; 2.64 | — |
| SECONDARY Number of Participants With Hypermobile Ehlers-Danlos Syndrome (hEDS) |
28 | — |
| SECONDARY Heart Rate Standing Minus Heart Rate Supine |
15; 12 | — |
Summary
The purpose of this study is to evaluate cognition in patients with postural tachycardia syndrome (POTS) while lying down and standing and to assess the prevalence of hypermobile Ehlers-Danlos Syndrome in POTS.
Eligibility Criteria
Inclusion Criteria
- Previously diagnosed with POTS, or healthy control
- Age between 13-60 years
- Participants may be any race, ethnicity, sex, or gender
- Able and willing to provide informed consent
Exclusion Criteria
- Inability to give, or withdrawal of, informed consent
- Age ≤ 13 or ≥ 61 years
- Prisoners
- Unable to stand
Data sourced from ClinicalTrials.gov (NCT03602482). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.